Head and Neck Squamous Cell Carcinoma
Conditions
Keywords
HNSCC
Brief summary
The purpose of this study is to assess the activity of 5-azacitidine in patients with Human Papilloma Virus (HPV)-positive and HPV- negative head and neck squamous cell carcinoma (HNSCC). The response activity will be determined by analyzing your tumor tissue prior to and after treatment with 5-azacitidine. Preliminary studies in mice bearing human head and neck cancers or head and neck cancer cells cultured in laboratories suggest that treatment with 5-azacitidine increases changes in cancer cells that lead to their death. This study is designed to determine if similar changes occur in cancer cells of patients with head and neck cancer. The study also aims to determine the amount of a specific type of protein, p53 before and after treatment. Research has shown that the p53 protein is associated with anti-tumor activity. Finally, this study is measuring the amount of a specific type of protein called interferon in your tumor tissue. Interferons are proteins made and released by the body in response to pathogens (disease causing agents) such as viruses, bacteria, or tumor cells. Interferons allow for communication between cells to trigger the protective defenses of the immune system that remove pathogens (disease causing agents) or tumors.
Detailed description
Primary Objectives: The primary objectives of this study are: • to determine the proportion of HPV-positive patients in whom 5-azacytidine increases APOBEC RNA expression. Secondary Objectives The secondary objectives of this study are: * to investigate response (proliferation, apoptosis), as well as reactivation of IFN pathways in patients treated with 5-azacitadine for HPV-positive and HPV-negative HNSCC. * to investigate the clinical activity of 5-azacitadine in patients with HPV-positive and HPV-negative HNSCC. * to investigate the safety of 5-azacitadine in patients with HPV-positive and HPV-negative HNSCC
Interventions
DRUG5-Azacitadine
Sponsors
Yale University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed p16 or HPV PCR positive HNSCC with surgically resectable disease 2. Age ≥18 years of age. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2 4. ANC greater than or equal to 1500, Hb greater than or equal to 8, platelet count greater than or equal to 100,000
Exclusion criteria
1. AST or ALT greater than 2.5 x ULN 2. Known brain metastases 3. Women must not be pregnant or breastfeeding 4. Known allergy to 5-azacitadine 5. Patients receiving any other investigational agents within 4 weeks of starting the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| tumor response | 6 months | The post-treatment biopsy will occur the day after the last injection of 5-azacytidine. 5-aza is currently FDA-approved and used for therapy of myelodysplastic syndrome. Pre- and post- 5-aza treatment tissue will be analyzed for proliferation (IHC-Ki-67), apoptosis (IHC-cleaved caspase-3, cleaved PARP-1), and for p53 protein (IHC, immunoblots), as well as p53, CDKN1A, MDM2, IFITs, and CCL5 mRNA levels (as described above). The primary outcome is the change from baseline of the p53 protein level in post-treatment vs. pre-treatment biopsies. Although tumor response may not be expected due to the short treatment course, the post-treatment vs. pre-treatment change from baseline of the gross tumor measurements will be used to measure tumor response. |
Countries
United States
Outcome results
None listed